Top

Strahlentherapie und Onkologie

Published in:

01-08-2012 | Original article

Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer

A phase I dose escalation study

Authors: J. Cvek, J. Kubes, E. Skacelikova, B. Otahal, P. Kominek, M. Halamka, D. Feltl

Published in: Strahlentherapie und Onkologie | Issue 8/2012

Abstract

Background and purpose

The present study was performed to evaluate the feasibility of a new, 5-week regimen of 70–75 Gy hyperfractionated accelerated radiotherapy with concomitant integrated boost (HARTCIB) for locally advanced, inoperable head and neck cancer.

Methods and materials

A total of 39 patients with very advanced, stage IV nonmetastatic head and neck squamous cell carcinoma (median gross tumor volume 72 ml) were included in this phase I dose escalation study. A total of 50 fractions intensity-modulated radiotherapy (IMRT) were administered twice daily over 5 weeks. Prescribed total dose/dose per fraction for planning target volume (PTV_tumor) were 70 Gy in 1.4 Gy fractions, 72.5 Gy in 1.45 Gy fractions, and 75 Gy in 1.5 Gy fractions for 10, 13, and 16 patients, respectively. Uninvolved lymphatic nodes (PTV_uninvolved) were irradiated with 55 Gy in 1.1 Gy fractions using the concomitant integrated boost.

Results

Acute toxicity was evaluated according to the RTOG/EORTC scale; the incidence of grade 3 mucositis was 51% in the oral cavity/pharynx and 0% in skin and the recovery time was ≤ 9 weeks for all patients. Late toxicity was evaluated in patients in complete remission according to the RTOG/EORTC scale. No grade 3/4 late toxicity was observed. The 1-year locoregional progression-free survival was 50% and overall survival was 55%.

Conclusion

HARTCIB (75 Gy in 5 weeks) is feasible for patients deemed unsuitable for chemoradiation. Acute toxicity was lower than predicted from radiobiological models; duration of dysphagia and confluent mucositis were particularly short. Better conformity of radiotherapy allows the use of more intensive altered fractionation schedules compared with older studies. These results suggest that further dose escalation might be possible when highly conformal techniques (e.g., stereotactic radiotherapy) are used.

Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955PubMed

Corvo R (2007) Evedence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156–170PubMedCrossRef

Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a metaanalysis. Lancet 368:843–854PubMedCrossRef

Mohan R et al (2000) Radiobiological considerations in the design of fractionation strategies for intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 46:619–630PubMedCrossRef

Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRef

Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940PubMedCrossRef

Skladowski K, Maciejewski B, Golen M et al (2006) Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 66:706–713PubMedCrossRef

Kubes J, Cvek J, Vondracek V et al (2011) Accelerated radiotherapy with concomitant boost technique (69,5 Gy/5 weeks). Strahlenther Onkol 187:651–655PubMedCrossRef

Stell G (2002) Basic clincal radiobiology. 3rd ed. Hodder Arnold, London

10.

Horiot JC, LeFur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241PubMedCrossRef

11.

Fowler JF, Harari PM, Leborgne F et al (2003) Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 69:161–168PubMedCrossRef

12.

Bonner JA, Harari PM, Giralt J (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef

13.

Dische S, Saunders M, Barrett A et al (1997) A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123–136PubMedCrossRef

14.

Giro C, Berger B, Bölke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166–171PubMedCrossRef

15.

McGinn CJ, Harari PM, Fowler JF et al (1993) Dose intensification in curative head and neck cancer radiotherapy-linear quadratic analysis and preliminary assessment of clinical results. Int J Radiat Oncol Biol Phys 27(2):363–369PubMedCrossRef

16.

Bourhis J, Lapeyre M, Tortochaux J et al (2006) Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 24:2873–2878PubMedCrossRef

17.

Tribius S, Kronemann S, Kilic Y et al (2009) Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:675–681PubMedCrossRef

18.

Eisbruch A, Harris J, Garden AS et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol Biol Phys 76:1333–1338PubMedCrossRef

19.

Gunn GB, Endres EJ, Parker B et al (2010) A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. Strahlenther Onkol 186:489–495PubMedCrossRef

20.

Harrison LB, Ferlito A, Shaha AR et al (2003) Current philosophy on the management of cancer of the base of the tongue. Oral Oncol 39:101–105PubMedCrossRef

21.

Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef

Title: Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer
A phase I dose escalation study
Authors: J. Cvek
J. Kubes
E. Skacelikova
B. Otahal
P. Kominek
M. Halamka
D. Feltl
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 8/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0128-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer

A phase I dose escalation study

Abstract

Background and purpose

Methods and materials

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and purpose

Methods and materials

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2012

Frühe glottische Karzinome im Erwachsenenalter

Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer

Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies

MRT-Mammographiescreening bei Patientinnen mit lobulärem Carcinoma in situ

Effekt einer adjuvanten Zoledronat-Therapie bei Mammakarzinom weiterhin unklar

Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma